To include your compound in the COVID-19 Resource Center, submit it here.

Pfizer’s $500M public biotech fund to complement late-stage BD activity

Pfizer getting early look at partnering opportunities through new fund

Pfizer is bolstering future business development opportunities with a $500 million fund designed to take small to mid-cap public biotechs with early-stage clinical assets to their next inflection points.

Pfizer Inc. (NYSE:PFE) Group President and CBO John Young told BioCentury the

Read the full 418 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers